Compass Therapeutics Inc [CMPX] stock prices are up 3.40% to $2.74 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The CMPX shares have gain 6.20% over the last week, with a monthly amount glided 9.60%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Leerink Partners upgraded its rating to Outperform on April 02, 2025, and kept the price target unchanged to $6. On February 24, 2025, Guggenheim initiated with a Buy rating and assigned a price target of $12 on the stock. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $12 on February 19, 2025. D. Boral Capital initiated its recommendation with a Buy and recommended $32 as its price target on December 23, 2024. Leerink Partners downgraded its rating to Market Perform for this stock on November 15, 2024, and downed its price target to $4. In a note dated September 16, 2024, Ladenburg Thalmann upgraded an Buy rating on this stock but restated the target price of $5.
The stock price of Compass Therapeutics Inc [CMPX] has been fluctuating between $0.83 and $4.08 over the past year. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Compass Therapeutics Inc [NASDAQ: CMPX] shares were valued at $2.74 at the most recent close of the market. An investor can expect a potential return of 118.98% based on the average CMPX price forecast.
Analyzing the CMPX fundamentals
Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -72.73%, Pretax Profit Margin comes in at -64.97%, and Net Profit Margin reading is -64.97%. To continue investigating profitability, this company’s Return on Assets is posted at -0.42, Equity is -0.42 and Total Capital is -0.53. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.66 points at the first support level, and at 2.58 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.80, and for the 2nd resistance point, it is at 2.86.
Ratios To Look Out For
It’s worth pointing out that Compass Therapeutics Inc [NASDAQ:CMPX]’s Current Ratio is 8.33. On the other hand, the Quick Ratio is 8.33, and the Cash Ratio is 2.75. Considering the valuation of this stock, the price to sales ratio is 445.75, the price to book ratio is 3.44.
Transactions by insiders
Recent insider trading involved Schuetz Thomas J., CHIEF EXECUTIVE OFFICER, that happened on May 27 ’25 when 10000.0 shares were purchased. Director, GORDON CARL L completed a deal on Apr 09 ’25 to sell 3.57 million shares. Meanwhile, Director ORBIMED ADVISORS LLC sold 3.57 million shares on Apr 09 ’25.
